New Breakthrough Treatment for Metastatic Castration-Resistant Prostate Cancer Arrives in Spain
Pfizer’s Talzenna Now Available in Spain: A Breakthrough for Metastatic Castration-Resistant Prostate Cancer Patients Pfizer has announced the availability of Talzenna (talazoparib) in Spain, marking a important milestone in the treatment of metastatic castration-resistant prostate cancer (mCRPC). This innovative therapy, the first adn only oral poly ADP-ribose polymerase (PARP) inhibitor in combination with enzalutamide, … Read more